Does Wellcare Cover Enbrel?
The verdict
Covered on most plans
Wellcare (Centene) covers Enbrel on the specialty tier with prior authorization and step therapy across its Medicare Part D and Medicaid plans. Two facts define this page: Enbrel's CMS-negotiated Medicare price is effective January 1, 2026, and no etanercept biosimilar can be marketed in the US until April 24, 2029 — step therapy must use a different biologic class. The $2,100 (2026) Part D out-of-pocket cap provides the primary Medicare cost protection.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Wellcare using your member ID.
Key facts
Enbrel is one of the first 10 Medicare Part D drugs with a CMS-negotiated price; those prices took effect January 1, 2026.
CMS Medicare Drug Price Negotiation Program, August 2023
No etanercept biosimilar can be marketed in the US until April 24, 2029 — both FDA-approved biosimilars (Erelzi, Eticovo) are blocked by patent litigation protecting Amgen's US Patent 8,163,522.
Center for Biosimilars; US District Court for the District of New Jersey, November 2021
The 2026 Part D out-of-pocket cap of $2,100 protects Wellcare Medicare members; at Enbrel's list price of approximately $8,150/month, most members reach the cap within 1–2 months.
CMS Medicare Part D 2026 parameters; Amgen Enbrel pricing
Medicare vs. commercial coverage
Whether Wellcare covers Enbrel depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Medicare Part D (Wellcare PDP/MA-PD): Enbrel is covered on the specialty tier with PA and step therapy, dispensed through a Wellcare-network specialty pharmacy. Enbrel is one of the first 10 Medicare Part D drugs with a CMS-negotiated price, effective January 1, 2026 — this lowers the program's drug cost. The 2026 Part D out-of-pocket cap of $2,100 limits annual member exposure; most Medicare members will reach the cap within 1–2 months given Enbrel's high list price (~$8,150/month estimate). Coinsurance is typically 25–33% after the deductible. Manufacturer savings cards are not available to Medicare beneficiaries. No etanercept biosimilar is marketed (blocked to 2029), so Wellcare cannot substitute a cheaper etanercept product.
Commercial / Employer
Group & marketplace plans
Wellcare has minimal commercial/employer plan presence; it primarily serves Medicare Part D and Medicaid managed-care populations. ACA/Individual coverage is limited — where offered, Enbrel is on the specialty tier with PA. Medicaid (Centene managed care): covered per state preferred-drug list with PA and step therapy; nominal cost-share. Because Centene manages Medicaid contracts across multiple states, exact PDL placement and step-therapy sequences vary by state — verify on your Wellcare drug list or state Medicaid PDL.
The 4 boxes you must tick to get approved
Commercial plans that will consider Enbrel require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
Meet all 4 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Enbrel actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
List price approximately $2,039.40 per 50 mg weekly syringe, approximately $8,150/month per Amgen (estimate). Treat as estimate — verify with pharmacy.
List price with no coverage — before any manufacturer savings card.
With coverage
Medicare Part D: typically 25–33% coinsurance after the deductible, capped at $2,100 for the year (2026 Part D OOP cap); CMS-negotiated price effective 1/1/2026 lowers the program's cost. Medicaid: nominal cost-share per state plan, $0–$4 typical. Manufacturer savings cards are not available to Medicare or Medicaid beneficiaries.
Typical monthly copay once prior authorization is approved.
Bridge program
Manufacturer savings cards (Enbrel Support program by Amgen) are not available to Medicare or Medicaid beneficiaries. Commercially insured patients (rare on Wellcare) should contact Amgen at 1-888-4ENBREL. Patients experiencing financial hardship may qualify for Amgen's patient-assistance program.
Reduced copay through the assistance program, where eligible.
All figures are estimates. Cost-share varies by plan and state. Confirm your specific out-of-pocket cost with Wellcare or your Medicaid case manager before starting treatment.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Check your Wellcare drug list or state Medicaid PDL
Visit wellcare.com or call the member services number on your Wellcare card to look up Enbrel (etanercept) on your plan's drug list. For Medicaid members, also check your state's Wellcare Medicaid preferred-drug list (PDL) for formulary status and step-therapy requirements.
- 2
Understand the step-therapy requirement before starting PA
Wellcare will typically require a trial of a preferred biologic — usually an adalimumab biosimilar (not an etanercept biosimilar, since none is available) — before Enbrel is approved. Discuss with your rheumatologist which agents satisfy the step-therapy requirement on your Wellcare plan before submitting the PA.
- 3
Have your rheumatologist submit the prior authorization
Ask your rheumatologist or specialist to submit the PA through Wellcare's portal or by calling the PA line on your member card. The submission should include your diagnosis, step-therapy history (prior biologic or DMARD tried), and clinical rationale. For Medicare members, confirm the Wellcare specialty pharmacy network for Enbrel dispensing.
Options if Wellcare won't cover Enbrel
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Adalimumab biosimilars (Amjevita, Hyrimoz, others)
Adalimumab biosimilars are likely the step-therapy option Wellcare requires before Enbrel. They share the TNF-inhibitor class and are typically less expensive than branded Enbrel. Ask your rheumatologist whether an adalimumab biosimilar is an appropriate option for your indication.
Methotrexate (MTX) or other conventional DMARDs
First-line conventional DMARDs such as methotrexate are typically Tier 1 generics on Wellcare plans and covered with minimal or no PA. A documented MTX trial and failure is commonly required before any biologic DMARD approval.
Amgen patient-assistance program (non-government plans only)
Amgen's EnSpring patient-support and patient-assistance programs are available to eligible commercially insured patients and uninsured patients who meet income criteria. Not available to Medicare or Medicaid beneficiaries. Contact Amgen at 1-888-4ENBREL.
These options are listed for information only — your own clinician decides what is appropriate for you.
❓Frequently Asked Questions
Yes. Wellcare covers Enbrel on the specialty tier on its Medicare Part D plans with PA and step therapy. Enbrel is one of the first 10 Medicare Part D drugs with a CMS-negotiated price effective January 1, 2026. The 2026 Part D out-of-pocket cap of $2,100 limits annual exposure. At Enbrel's list price (~$8,150/month), most Medicare members reach the cap within 1–2 months. Verify your specific plan's cost-share with Wellcare.
No. Two etanercept biosimilars — Erelzi and Eticovo — are FDA-approved but cannot be marketed in the US due to patent litigation. Per court rulings and the Center for Biosimilars, neither can launch until April 24, 2029. So unlike Humira, Wellcare cannot substitute a cheaper etanercept biosimilar. Step therapy instead routes through a preferred agent in a different biologic class, such as an adalimumab biosimilar.
CMS selected Enbrel as one of the first 10 Medicare Part D drugs for price negotiation (announced August 29, 2023); the negotiated prices became effective January 1, 2026. The negotiation primarily lowers what the Medicare program pays for Enbrel. Your out-of-pocket cost as a Wellcare Medicare member is mainly governed by the 2026 Part D out-of-pocket cap of $2,100, not the negotiated price itself. Confirm cost-share specifics with Wellcare.
Yes. Wellcare's Medicaid managed-care plans cover Enbrel per state preferred-drug list with PA and step therapy. Nominal cost-share of $0–$4 is typical. Because Centene manages Medicaid contracts across multiple states, exact requirements vary by state PDL. Verify on your state's Wellcare Medicaid drug list. Manufacturer savings cards are not available to Medicaid beneficiaries.
Step therapy is the standard for specialty biologic DMARDs across commercial, Medicare, and Medicaid plans. Plans require documented failure of at least one preferred biologic or conventional DMARD (such as methotrexate) before approving a more expensive agent like Enbrel. For Enbrel specifically, the step agent is typically an adalimumab biosimilar or methotrexate, not an etanercept biosimilar (since none is marketed). Your rheumatologist can guide which step-therapy agent satisfies your plan's requirement.
Related Articles
Does Aetna Cover Vyvanse? 2026 CVS Caremark Formulary
Aetna covers Vyvanse via CVS Caremark — generic lisdexamfetamine preferred, brand non-preferred. 70 mg/day QL per Policy 5.60.024; age-22 PA required.
Read moreDoes Aetna Cover Prolia? CVS Caremark Medical Benefit | Curex
Aetna covers Prolia under the medical benefit with PA — a q6-month clinic injection, not Part D. Jubbonti biosimilar now preferred on CVS Caremark.
Read moreDoes Anthem Cover Adderall? 2026 Coverage Guide | Curex
Anthem covers Adderall through CarelonRx — generic preferred, brand non-preferred. Step therapy may apply on some plans. Verify your Anthem plan.
Read moreDoes Anthem Cover Contrave? 2026 Brand Coverage Guide | Curex
Anthem covers Contrave only if your plan has a weight-loss benefit. Many plans carve it out. CurAccess ~$99/mo is often the fastest path.
Read moreDoes Aetna Cover Contrave? 2026 CVS Caremark Guide | Curex
Aetna (CVS Caremark) often excludes Contrave under AOM carve-outs. Where covered, CVS BMI prior auth applies. Medicare bars it by law. CurAccess ~$99/mo.
Read moreDoes Aetna Cover Forteo? 2026 Coverage Guide
Aetna (CVS) often excludes brand Forteo in favor of generic teriparatide or Bonsity. Teriparatide is covered with PA and bisphosphonate step therapy. 2026.
Read moreThis content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Wellcare before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation.